News >

Immunotherapy Could Have Role in Frontline HCC

Angelica Welch
Published: Monday, Dec 17, 2018

Michael J. Pishvaian, MD, PhD

Michael J. Pishvaian, MD, PhD
In the search to establish new therapeutic options for patients with advanced hepatocellular carcinoma (HCC), immunotherapy has become a frontrunner in many clinical trials in the first-line setting, according to Michael J. Pishvaian, MD, PhD.

For example, data presented at the 2018 ESMO Congress on the combination of the PD-L1 inhibitor atezolizumab (Tecentriq) and the VEGF inhibitor bevacizumab (Avastin) showed durable response rates as a frontline regimen for this population. The confirmed investigator-assessed objective response rate (ORR) in the study was 32% per RECIST v1.1 criteria. More than half of responders maintained their response for at least 6 months, and about one-quarter maintained response for at least 12 months.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication